ART21934

Asset

Targets TROP2 and delivers a payload that locks PARP onto chromatin, causing DNA double-strand breaks and cell death.

Stage
Preclinical
Modality
Antibody
Target
Not known
0
Indications
0
Trials
1
Developer

Indications

1
  • No named disease

    Preclinical, artios.com, 10 Oct 2026

In the full profile

  • Owner and partners1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets